Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test
  • Research

Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test

  • The Pharma Data
  • March 4, 2025

Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test Revvity, Inc. (NYSE: RVTY) has announced the launch of EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG), which has received the CE…

Read MoreRevvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test
Surescripts 2024 Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access
  • Press Releases

Surescripts 2024 Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access

  • The Pharma Data
  • March 4, 2025

Surescripts 2024 Annual Impact Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access Surescripts, the nation’s leading health information network, has released its highly anticipated 2024 Annual…

Read MoreSurescripts 2024 Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access
LabVantage Launches LIMS 8.9 to Boost Lab Productivity & Efficiency
  • Research

LabVantage Launches LIMS 8.9 to Boost Lab Productivity & Efficiency

  • The Pharma Data
  • March 4, 2025

LabVantage Solutions Unveils LIMS 8.9: Transforming Lab Productivity and Efficiency LabVantage Solutions, Inc., a global leader in laboratory informatics, has announced the launch of LabVantage 8.9, the latest evolution of…

Read MoreLabVantage Launches LIMS 8.9 to Boost Lab Productivity & Efficiency
Tenovi and GenieMD Partner to Expand Remote Care and Improve Medication Adherence
  • Business

Tenovi and GenieMD Partner to Expand Remote Care and Improve Medication Adherence

  • The Pharma Data
  • March 4, 2025

Tenovi and GenieMD Partner to Revolutionize Remote Care and Improve Medication Adherence GenieMD and Tenovi have announced a groundbreaking partnership aimed at expanding access to remote care and improving medication…

Read MoreTenovi and GenieMD Partner to Expand Remote Care and Improve Medication Adherence
  • Business

Repare Therapeutics Shares Business, Clinical Update & 2024 Financial Results

  • The Pharma Data
  • March 4, 2025

Repare Therapeutics Shares Business, Clinical Update & 2024 Financial Results Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, has released its financial results for…

Read MoreRepare Therapeutics Shares Business, Clinical Update & 2024 Financial Results
  • Research

Protagonist and Takeda Report Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera

  • The Pharma Data
  • March 4, 2025

Protagonist and Takeda Announce Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline…

Read MoreProtagonist and Takeda Report Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera
Guardian Pharmacy Services Reports Q4 & Full-Year 2024 Results, 2025 Outlook & Earnings Call Date
  • News

Guardian Pharmacy Services Reports Q4 & Full-Year 2024 Results, 2025 Outlook & Earnings Call Date

  • The Pharma Data
  • March 4, 2025

Guardian Pharmacy Services Reports Preliminary Q4 and Full-Year 2024 Results, Provides 2025 Guidance Guardian Pharmacy Services, Inc. (“Guardian” or the “Company”) (NYSE: GRDN), one of the largest long-term care (LTC)…

Read MoreGuardian Pharmacy Services Reports Q4 & Full-Year 2024 Results, 2025 Outlook & Earnings Call Date
Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®
  • Regulatory

Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®

  • The Pharma Data
  • March 4, 2025

Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra®…

Read MoreCelltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®
  • Research

QIAGEN Files Legal Action to Protect QuantiFERON IP in TB Testing

  • The Pharma Data
  • March 3, 2025

QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint…

Read MoreQIAGEN Files Legal Action to Protect QuantiFERON IP in TB Testing
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings
  • Business

SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings

  • The Pharma Data
  • March 1, 2025

SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings SmithRx, a transparent and fully pass-through modern pharmacy benefits manager (PBM), has announced a significant expansion of its Connect 360 Autoimmune Program. This…

Read MoreSmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings
Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio
  • Business

Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio

  • The Pharma Data
  • March 1, 2025

Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio Demetra Holding, a pioneering and independent international medical device company specializing in anti-infective cements, spacers, and biomaterials for orthopedic…

Read MoreDemetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio
Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer
  • News

Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth

  • The Pharma Data
  • March 1, 2025

Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth Wedgewood, the nation’s largest provider of compounded veterinary medications and pharmacy solutions, has appointed Jessica Knopp-Gwynne as Chief Revenue…

Read MoreWedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • UCB Expands Immunology Portfolio with Acquisition of Candid Therapeutics, Advancing Novel T-Cell Engager Strategy
  • J&J Statement on FDA Approval of STELARA® for Pediatric Crohn’s Disease
  • Incyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.